AAA
SABS icon

Affinity Asset Advisors’s SAB Biotherapeutics SABS Stock Holding History

Affinity Asset Advisors’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.95M Buy
1,525,000
+950,000
+165% +$3.53M 0.27% 73
2026
Q1 		$2.2M Buy
+575,000
New +$2.29M 0.11% 93

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Affinity Asset Advisors's SABS Position: Q2 2026 in Review

Affinity Asset Advisors increased its SAB Biotherapeutics (SABS) stake by 165% in Q2 2026, buying an estimated $3.53M and bringing the position to 1,525,000 shares worth $5.95M. The position accounts for 0.27% of the portfolio, ranked #73.

Affinity Asset Advisors first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Affinity Asset Advisors held 1,525,000 shares of SAB Biotherapeutics worth $5.95M as of Q2 2026.
  • Affinity Asset Advisors bought 950,000 SAB Biotherapeutics shares in Q2 2026, an estimated $3.53M.
  • SAB Biotherapeutics made up 0.27% of Affinity Asset Advisors's portfolio in Q2 2026, its #73 holding.
  • Affinity Asset Advisors first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.